Asia Pacific Pharmaceutical Blister Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

Asia Pacific Pharmaceutical Blister Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

The Asia Pacific Pharmaceutical Blister Packaging Market size is estimated at USD 9.68 billion in 2024, and is expected to reach USD 13.16 billion by 2029, growing at a CAGR of 6.32% during the forecast period (2024-2029).

The increasing incidence of new diseases, growth in regulatory norms, focus on people's health management, customers being more informed, and the increase in OTC drugs boost the growth of the pharmaceutical blister packaging market in the region.

Key Highlights

• Extended shelf life is essential for the pharmaceutical sector, considering consumers store their drugs in a temperature-variant atmosphere that can harm unprotected medicines. Products include capsules, tablets, and sterile products.
• The growing population in developing countries such as India, rising health awareness, and increasing life expectancy can be attributed to the market's growth. The number of chronic disease cases is surging rapidly. According to WHO, over 20% of the country's population suffers from at least one of the chronic diseases, such as cancer, heart ailments, respiratory diseases, and diabetes, that are estimated to cost USD 6.2 trillion during the period 2012-2030. To prevent economic burdens in the coming years, pharmaceutical companies are researching and developing medicines to drive market growth.
• In August 2023, Aptar CSP Technologies partnered strategically with Porton Pharmatech to bring Activ-Blister solutions to the Asia-Pacific (APAC) region. The move followed the commercialization and approval of Activ-Blister technology with two HIV medications. The partnership with Porton provided pharma developers in the APAC region access to a local development and manufacturing resource for leveraging Aptar CSP's Activ-Blister solutions to protect sensitive drugs. Such collaborations drive market growth.
• In the pharmaceutical industry, blister packaging offers various solutions, such as PVC, PCTFE, PVDC, and thermoform blisters for less sensitive products. However, the unfitness for heavy items and stringent regulations in developing countries are anticipated to restrain market growth.
• Nationwide lockdowns, government regulations, and the steady rise in the national disease rate during the pandemic had far-reaching financial impacts on the market, especially in the early stages. However, the demand for packaging increased as the disease raised the demand for pharmaceutical products and concerns about the virus's ability to survive on the packaging surface.

Asia Pacific Pharmaceutical Blister Packaging Market Trends

The Aging Population and the Prevalence of Diseases are Expected to Drive Market Growth

• The Asia-Pacific region is undergoing profound population changes. All countries in the region are aging at an exceptional pace, although the timing and speed of this transition vary across the region. According to the United Nations ESCAP, in 2016, about 12.4% of the population in the area was 60 years or older; this is projected to grow to 1.3 billion people by 2050.
• The infectious disease hindrance remains substantial in countries owing to the presence of low and lower-middle-income groups, while mortality and morbidity associated with ignored tropical diseases, HIV infection, tuberculosis, and malaria remain elevated. Moreover, deaths from emerging and re-emerging infections, compared to seasonal and endemic conditions, have continued throughout the twenty-first century. This points to a possible new era of infectious disease, defined by outbreaks of emerging, re-emerging, and endemic pathogens that spread quickly, aided by global connectivity and shifted ranges owing to climate change.
• According to a study by the National Center for Biotechnology Information (NCBI), non-communicable diseases (NCDs) lead to significant mortality and morbidity. The common NCDs are cardiovascular diseases (CVD), diabetes, cancer, and chronic respiratory diseases. NCD-related deaths in Asia-Pacific have increased; NCDs are the primary cause of deaths and disease burden in the region.
• According to the National Bureau of Statistics of China, the population above 64 was 15.4% in 2023, an increase from 13.5% in 2020. Companies operating in the region are encouraged to develop independent research and development teams to investigate cutting-edge, environmentally friendly, secure, helpful, and sustainable blister packaging.
• AstraZeneca declared plans to build a production facility for its regional headquarters in Qingdao, Shandong. China is the company's second-largest market after the United States. AstraZeneca will continue to increase its confidence in investing in China to encourage the growth of Qingdao's biopharmaceutical industry and support the National Health Vision 2030.

India is Expected to Witness Growth Due to the Rising Population

• The increasing market for safety and protection to boost product longevity is an essential factor fueling the growth of the blister packaging market. Government initiatives to improve medical facilities will further drive market growth in India. For instance, the Pradhan Mantri Ayushman Bharat - Health Infrastructure Mission (PM-ABHIM) is one of the government's significant pan-India infrastructure projects to boost the country's health infrastructure, surveillance, and health research.
• In addition, the government has designed the Free Diagnostics Service Initiative to cut direct healthcare costs and out-of-pocket charges. The rise in disposable income is a significant factor projected to promote India's pharmaceutical packaging market expansion.
• The pharmaceutical blister packaging market is fueled by population growth, urbanization, and changing consumer preferences. According to UN estimates, India surpassed China as the most populous country in 2023. Also, according to the International Monetary Fund (IMF), the total estimated population in 2024 is expected to reach 1,441.72 million, an increase from 1,396.39 million in 2020.
• Pharmaceutical manufacturers are focusing on delivering more granular information on pharmaceutical blister products. With additional sophisticated serialization of prescription and non-prescription pharmaceuticals, the healthcare sector can guarantee that the medicine is not counterfeit and that the right patient gets the correct dose and medication at the right time. 2D code that contains product, dose, batch code, and expiry date information on individual blister packs, or even coding each pocket containing a tablet, can help lower the number of cases where patients unintentionally obtain the wrong medicine or dose.
• According to a study by A.P. Moller-Maersk in February 2024, India's pharmaceutical supply chain underwent significant transformation spurred by globalization, technological advancements, regulatory shifts, and rising healthcare product demand. The focus shifted from manual and transactional methods to automation and strategic innovation. Such transformation in the pharmaceutical sector would further boost the market for blister packaging.

Asia Pacific Pharmaceutical Blister Packaging Industry Overview

The Asia-Pacific pharmaceutical blister packaging market is fragmented, with various significant players such as Amcor Limited, Constantia Flexibles, Westrock Company, Klockner Pentaplast Group, and Sonoco Products Company. The players are focused on expanding their business in the region through acquisitions, collaborations, mergers, etc.

• January 2024: TekniPlex Healthcare partnered with Alpek Polyester to launch a pharmaceutical-grade polyethylene terephthalate (PET) blister film featuring 30% post-consumer recycled (PCR) monomers. The company stated that when the blister film is combined with its Teknilid Push polyester lidding, the film-plus-lidding blister system is completely recyclable in the polyester recycling stream where the infrastructure exists.
• July 2023: Constantia Flexibles unveiled its latest pharmaceutical packaging solution, the cold-form foil REGULA CIRC. This cutting-edge technology set a unique standard for sustainability in blister packaging, offering many advantages. With circularity at its core, REGULA CIRC complies with future regulations and legislation, providing a total barrier solution that meets the highest sustainable packaging standards.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support